Mer­ck KGaA posts mixed da­ta from their big PhI­Ib MS study on evo­bru­ti­nib — spurring plen­ty of ques­tions

Mer­ck KGaA is post­ing some of their mid-stage da­ta from a tri­al of their BTK in­hibitor evo­bru­ti­nib for mul­ti­ple scle­ro­sis. But de­spite a bold boast that the drug rep­re­sents just how in­no­v­a­tive their in-house R&D group is, the da­ta are dis­tinct­ly mixed.

On the pri­ma­ry end­point, re­searchers claimed a clear win for the once-dai­ly dose of 75 mg top­ping out with a sta­tis­ti­cal­ly sig­nif­i­cant p val­ue of 0.0015 in re­duc­ing the num­ber of le­sions mea­sured among pa­tients in the drug arm. The twice dai­ly dose came in at 0.03 while the low dose failed. That’s not un­usu­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.